Neuland Laboratories Approves FY2026 Results, Recommends Dividend, and Names Additional Director
Neuland Laboratories Limited announced the approval of its audited financial results and key corporate actions following a Board of Directors meeting held on May 12, 2026. The Board recommended a final dividend for the financial year 2025-26 and approved the appointment of Dr. Mauricio Futran as an Additional Director. Furthermore, the company detailed plans for enhancing its manufacturing capacity at its Unit 1 in Telangana.Financial Performance and Dividend Recommendation
The Board of Directors approved the Audited Financial Results (Standalone & Consolidated) for the year ended March 31, 2026. The company noted that the Statutory Auditors, M S K A & Associates LLP, issued audit reports with an unmodified opinion on the financial statements.The Board also recommended the payment of a final dividend of Rs. 34/- (340 %) per equity share on a face value of Rs. 10 each for the financial year 2025-26. The dividend is scheduled for payment on or after five days from the date of declaration by the shareholders at the 42nd Annual General Meeting (AGM).
The financial data for the year ended March 31, 2026, showed the following consolidated figures:
| Metric | Year Ended March 31, 2026 (Audited) | Year Ended March 31, 2025 (Audited) |
|---|---|---|
| Total Income | 78,870.85 lakhs | 149,734.66 lakhs |
| Total Expenses | 50,121.37 lakhs | 122,742.12 lakhs |
| Profit Before Tax | 28,749.48 lakhs | 34,632.90 lakhs |
| Profit for the Period/Year | 21,267.26 lakhs | 26,010.81 lakhs |
| Total Comprehensive Income | 21,390.92 lakhs | 26,006.33 lakhs |
Consolidated Balance Sheet Highlights (As at March 31, 2026):
| Particulars | 31.03.2026 (lakhs) | 31.03.2025 (lakhs) |
|---|---|---|
| Total Non-current Assets | 1,44,700.89 | 1,04,038.47 |
| Total Current Assets | 1,48,312.88 | 1,13,949.69 |
| Total Assets | 2,93,013.77 | 2,17,988.16 |
| Total Equity | 1,87,447.29 | 1,52,480.63 |
| Total Liabilities | 1,05,566.48 | 65,507.53 |
| Total Equity and Liabilities | 2,93,013.77 | 2,17,988.16 |
Governance and Operational Updates
Additional Director AppointmentDr. Mauricio Futran (DIN: 11699767) was appointed as an Additional Director of the Company, categorized as Non-Executive Non-Independent. This appointment is effective from May 12, 2026, following the recommendation of the Nomination and Remuneration Committee and is subject to shareholder approval at the ensuing AGM.
Annual General Meeting (AGM)
The Board approved the convening of the 42nd AGM of the shareholders for Tuesday, August 4, 2026. The record date for determining shareholders eligible to receive the final dividend for the financial year ended March 31, 2026, has been fixed as July 24, 2026.
Manufacturing Capacity Expansion
The company also detailed plans for the enhancement of its capacity at Unit 1, located at Bonthapally Village, Gummadidala Mandal, Sangareddy District, Telangana. Key details regarding the proposed capacity addition include:
| Parameter | Detail |
|---|---|
| Existing Capacity | 256KL |
| Existing Utilization | 91% |
| Proposed Capacity Addition | 120.5KL |
| Period for Addition | 12 to 18 months |
| Investment Required | ₹ 143.4 crores (incl GST) |
| Mode of Financing | Internal accruals and borrowings |
| Rationale | To maintain and cater to the growing demand of customers. |
Cash Flow Analysis Summary
The consolidated cash flow statement highlighted the following key figures for the year:| Activity | Year Ended March 31, 2026 (₹ lakhs) | Year Ended March 31, 2025 (₹ lakhs) |
|---|---|---|
| Cash generated from operating activities | 45,020.81 | 39,213.04 |
| Net cash used in investing activities | (42,373.29) | (29,815.59) |
| Net cash flow from financing activities | 2,097.54 | 2,496.10 |
| Net increase in cash and cash equivalents | (5,607.71) | 4,420.93 |
The company's segment revenue breakdown for the year ended March 31, 2026, shows the following distribution:
| Segment | Revenue from Operations (lakhs) |
|---|---|
| India | 12,150.46 |
| Europe | 29,661.19 |
| USA and North America | 31,366.44 |
| Rest of the world | 4,446.94 |
| Total Revenue from Operations | 77,625.03 |
NEULANDLAB Stock Price Movement
Neuland Laboratories Limited shares today slipped by 2.56% to settle at ₹17,003 after a significant move in the Pharma sector. The stock saw 106,204 shares traded, finding support near its day low of ₹16,905.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: